Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells

Dongkyu Kim, Dokyoung Lee, Yeon Lim Jang, Su Young Chae, Donghoon Choi, Ji Hoon Jeong, Sun Hwa Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Clinical applications of RNA interference-based therapeutics such as small interfering RNAs (siRNAs) have been limited mainly due to low intracellular delivery efficiency in vitro and in vivo. In this study, facially amphipathic deoxycholic acid (DA)-modified polyethyleneimine (PEI 1.8) (DA-PEI 1.8) was synthesized and used as a potent carrier system for siRNA targeted against matrix metalloproteinase-2 (MMP-2) to inhibit the migration of vascular smooth muscle cells (SMCs), which is the major pathomechanism in the development of atherosclerosis and restenosis after arterial injury. A representative facial amphipathic bile acid DA having a high membrane permeability was conjugated to the terminal amine groups of the low molecular weight PEI 1.8 via amide bonds. The DA-PEI 1.8 conjugates formed self-assembled nanoparticles with siRNA molecules in an aqueous phase and the DA-PEI 1.8/siRNA polyplexes became stabilized and condensed as particle incubation time increased from 0 to 4 h. Both cellular internalization and target gene silencing were enhanced as the DA-PEI 1.8/siRNA polyplexes stabilized. When vascular SMCs were transfected with MMP-2 siRNA, the DA-PEI 1.8/siRNA polyplex formulation led to a significant decrease in MMP-2 gene expression, resulting in the suppression of cell migration. These results suggest that the DA-PEI 1.8/MMP-2 siRNA delivery system may be useful in anti-restenotic treatment for various vasculoproliferative disorders such as atherosclerosis, in-stent restenosis, and vein graft failure.

Original languageEnglish
Pages (from-to)14-23
Number of pages10
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume81
Issue number1
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

Polyethyleneimine
Deoxycholic Acid
Matrix Metalloproteinase 2
Vascular Smooth Muscle
Small Interfering RNA
Smooth Muscle Myocytes
Atherosclerosis
Gene Silencing
RNA Interference
Bile Acids and Salts
Amides
Nanoparticles
Cell Movement
Amines
Stents
Veins
Permeability
Molecular Weight
Transplants
Gene Expression

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science

Cite this

Kim, Dongkyu ; Lee, Dokyoung ; Jang, Yeon Lim ; Chae, Su Young ; Choi, Donghoon ; Jeong, Ji Hoon ; Kim, Sun Hwa. / Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. In: European Journal of Pharmaceutics and Biopharmaceutics. 2012 ; Vol. 81, No. 1. pp. 14-23.
@article{5a32ec2e14f64d7aa1bc6e3f41acfbeb,
title = "Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells",
abstract = "Clinical applications of RNA interference-based therapeutics such as small interfering RNAs (siRNAs) have been limited mainly due to low intracellular delivery efficiency in vitro and in vivo. In this study, facially amphipathic deoxycholic acid (DA)-modified polyethyleneimine (PEI 1.8) (DA-PEI 1.8) was synthesized and used as a potent carrier system for siRNA targeted against matrix metalloproteinase-2 (MMP-2) to inhibit the migration of vascular smooth muscle cells (SMCs), which is the major pathomechanism in the development of atherosclerosis and restenosis after arterial injury. A representative facial amphipathic bile acid DA having a high membrane permeability was conjugated to the terminal amine groups of the low molecular weight PEI 1.8 via amide bonds. The DA-PEI 1.8 conjugates formed self-assembled nanoparticles with siRNA molecules in an aqueous phase and the DA-PEI 1.8/siRNA polyplexes became stabilized and condensed as particle incubation time increased from 0 to 4 h. Both cellular internalization and target gene silencing were enhanced as the DA-PEI 1.8/siRNA polyplexes stabilized. When vascular SMCs were transfected with MMP-2 siRNA, the DA-PEI 1.8/siRNA polyplex formulation led to a significant decrease in MMP-2 gene expression, resulting in the suppression of cell migration. These results suggest that the DA-PEI 1.8/MMP-2 siRNA delivery system may be useful in anti-restenotic treatment for various vasculoproliferative disorders such as atherosclerosis, in-stent restenosis, and vein graft failure.",
author = "Dongkyu Kim and Dokyoung Lee and Jang, {Yeon Lim} and Chae, {Su Young} and Donghoon Choi and Jeong, {Ji Hoon} and Kim, {Sun Hwa}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.ejpb.2012.01.013",
language = "English",
volume = "81",
pages = "14--23",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "1",

}

Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. / Kim, Dongkyu; Lee, Dokyoung; Jang, Yeon Lim; Chae, Su Young; Choi, Donghoon; Jeong, Ji Hoon; Kim, Sun Hwa.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 81, No. 1, 01.05.2012, p. 14-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells

AU - Kim, Dongkyu

AU - Lee, Dokyoung

AU - Jang, Yeon Lim

AU - Chae, Su Young

AU - Choi, Donghoon

AU - Jeong, Ji Hoon

AU - Kim, Sun Hwa

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Clinical applications of RNA interference-based therapeutics such as small interfering RNAs (siRNAs) have been limited mainly due to low intracellular delivery efficiency in vitro and in vivo. In this study, facially amphipathic deoxycholic acid (DA)-modified polyethyleneimine (PEI 1.8) (DA-PEI 1.8) was synthesized and used as a potent carrier system for siRNA targeted against matrix metalloproteinase-2 (MMP-2) to inhibit the migration of vascular smooth muscle cells (SMCs), which is the major pathomechanism in the development of atherosclerosis and restenosis after arterial injury. A representative facial amphipathic bile acid DA having a high membrane permeability was conjugated to the terminal amine groups of the low molecular weight PEI 1.8 via amide bonds. The DA-PEI 1.8 conjugates formed self-assembled nanoparticles with siRNA molecules in an aqueous phase and the DA-PEI 1.8/siRNA polyplexes became stabilized and condensed as particle incubation time increased from 0 to 4 h. Both cellular internalization and target gene silencing were enhanced as the DA-PEI 1.8/siRNA polyplexes stabilized. When vascular SMCs were transfected with MMP-2 siRNA, the DA-PEI 1.8/siRNA polyplex formulation led to a significant decrease in MMP-2 gene expression, resulting in the suppression of cell migration. These results suggest that the DA-PEI 1.8/MMP-2 siRNA delivery system may be useful in anti-restenotic treatment for various vasculoproliferative disorders such as atherosclerosis, in-stent restenosis, and vein graft failure.

AB - Clinical applications of RNA interference-based therapeutics such as small interfering RNAs (siRNAs) have been limited mainly due to low intracellular delivery efficiency in vitro and in vivo. In this study, facially amphipathic deoxycholic acid (DA)-modified polyethyleneimine (PEI 1.8) (DA-PEI 1.8) was synthesized and used as a potent carrier system for siRNA targeted against matrix metalloproteinase-2 (MMP-2) to inhibit the migration of vascular smooth muscle cells (SMCs), which is the major pathomechanism in the development of atherosclerosis and restenosis after arterial injury. A representative facial amphipathic bile acid DA having a high membrane permeability was conjugated to the terminal amine groups of the low molecular weight PEI 1.8 via amide bonds. The DA-PEI 1.8 conjugates formed self-assembled nanoparticles with siRNA molecules in an aqueous phase and the DA-PEI 1.8/siRNA polyplexes became stabilized and condensed as particle incubation time increased from 0 to 4 h. Both cellular internalization and target gene silencing were enhanced as the DA-PEI 1.8/siRNA polyplexes stabilized. When vascular SMCs were transfected with MMP-2 siRNA, the DA-PEI 1.8/siRNA polyplex formulation led to a significant decrease in MMP-2 gene expression, resulting in the suppression of cell migration. These results suggest that the DA-PEI 1.8/MMP-2 siRNA delivery system may be useful in anti-restenotic treatment for various vasculoproliferative disorders such as atherosclerosis, in-stent restenosis, and vein graft failure.

UR - http://www.scopus.com/inward/record.url?scp=84862779763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862779763&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2012.01.013

DO - 10.1016/j.ejpb.2012.01.013

M3 - Article

C2 - 22311297

AN - SCOPUS:84862779763

VL - 81

SP - 14

EP - 23

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -